EASD 2025|HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
HONG KONG, Sep 17, 2025 – (ACN Newswire)–HighTide Therapeutics, Inc. (2511. HK), a medical phase biopharmaceutical business concentrating on the advancement of multifunctional multi-targeted treatments for metabolic illness, revealed that information from the Phase 3 SYMPHONY 2 trial examining the security and effectiveness of HTD1801 in clients with type 2 diabetes mellitus (T2DM) is existing at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
HTD1801, is a first-in-class anti-inflammatory metabolic modulator that triggers AMPK and prevents the NLRP3 inflammasome. These paths assemble at the nexus of metabolic dysregulation beyond glucose control and persistent swelling. This randomized, double-blind, placebo-controlled research study examined the effectiveness and security of HTD1801 compared to placebo in clients with T2DM improperly managed with metformin. The main endpoint of Symphony 2 was modification from standard in HbA1c to Week 24 compared to placebo. Secondary endpoints checked out results on cardiovascular, metabolic, and kidney comorbidities to evaluate it’s prospective as a detailed Cardiovascular-Kidney-Metabolic treatment.
Qualified clients were randomized 2:1 to HTD1801 1000 mg BID (N=365) or placebo (N=184). The research study satisfied the main endpoint at Week 24, with HTD1801-treated clients accomplishing an LS mean modification in HbA1c of -1.21% compared to -0.68% with placebo (LS mean diff: -0.53, p<
